Jennison Associates LLC raised its stake in Natera Inc (NASDAQ:NTRA) by 24.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,434,727 shares of the medical research company’s stock after purchasing an additional 869,420 shares during the period. Jennison Associates LLC owned 0.06% of Natera worth $122,310,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in NTRA. Kornitzer Capital Management Inc. KS lifted its holdings in shares of Natera by 64.2% in the first quarter. Kornitzer Capital Management Inc. KS now owns 513,141 shares of the medical research company’s stock worth $10,581,000 after acquiring an additional 200,550 shares during the last quarter. Lisanti Capital Growth LLC acquired a new position in shares of Natera in the second quarter valued at approximately $5,717,000. AGF Investments Inc. increased its stake in shares of Natera by 240.0% in the second quarter. AGF Investments Inc. now owns 170,000 shares of the medical research company’s stock valued at $4,689,000 after buying an additional 120,000 shares during the period. Swiss National Bank increased its stake in shares of Natera by 10.0% in the second quarter. Swiss National Bank now owns 80,500 shares of the medical research company’s stock valued at $2,220,000 after buying an additional 7,300 shares during the period. Finally, Dupont Capital Management Corp increased its stake in shares of Natera by 78.6% in the second quarter. Dupont Capital Management Corp now owns 51,953 shares of the medical research company’s stock valued at $1,433,000 after buying an additional 22,866 shares during the period. Hedge funds and other institutional investors own 86.89% of the company’s stock.
Several research analysts have recently issued reports on the company. Craig Hallum upped their price objective on Natera from $29.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. BidaskClub raised Natera from a “hold” rating to a “buy” rating in a research note on Friday, August 9th. Canaccord Genuity upped their price objective on Natera from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Friday. Zacks Investment Research raised Natera from a “sell” rating to a “hold” rating in a research note on Friday, August 9th. Finally, Piper Jaffray Companies upped their price objective on Natera from $28.00 to $32.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $32.57.
NASDAQ:NTRA traded up $1.33 on Friday, reaching $32.32. 777,154 shares of the stock traded hands, compared to its average volume of 802,871. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -15.03 and a beta of 1.51. The company’s 50 day moving average is $27.60 and its 200-day moving average is $22.17. The company has a current ratio of 2.54, a quick ratio of 2.42 and a debt-to-equity ratio of 1.10. Natera Inc has a 1-year low of $11.08 and a 1-year high of $33.25.
Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, August 7th. The medical research company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09. The business had revenue of $74.36 million during the quarter, compared to the consensus estimate of $66.77 million. Natera had a negative net margin of 46.78% and a negative return on equity of 273.92%. The company’s revenue for the quarter was up 17.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.62) EPS. On average, equities research analysts forecast that Natera Inc will post -2.1 EPS for the current fiscal year.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: Municipal Bonds
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.